Dermatology Therapeutics was Aclaris Therapeutics’s largest product and service line in fiscal 2025, bringing in $5.95M of $7.83M (76%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Licensing | $25.10M | $28.21M | — | — | |||||
| Dermatology Therapeutics | — | — | $16.18M | $5.95M | |||||
| Contract Research | $4.40M | $3.04M | $2.54M | $1.87M | |||||
| Other | $257.00K | — | — | — | |||||
| Other Revenue | — | — | — | — | |||||
| Total | $29.75M | $31.25M | $18.72M | $7.83M |
Aclaris Therapeutics brought in $7.83M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 58.2% from $18.72M in fiscal 2024. Dermatology Therapeutics was the largest at $5.95M (76.1%), ahead of Contract Research at $1.87M (23.9%).
Compared with fiscal 2024, Contract Research fell 26.3% to $1.87M and Dermatology Therapeutics fell 63.2% to $5.95M.
Aclaris Therapeutics began breaking out Dermatology Therapeutics in fiscal 2024, when it brought in $16.18M. Aclaris Therapeutics stopped reporting Licensing ($28.21M in fiscal 2023) and Other ($257.00K in fiscal 2022) as separate lines.
Aclaris Therapeutics (ACRS) reports its revenue by product and service. In fiscal 2025, Dermatology Therapeutics was its largest product and service line, bringing in $5.95M (76.1% of the total), followed by Contract Research at $1.87M (23.9%).
Dermatology Therapeutics was Aclaris Therapeutics' largest product and service line in fiscal 2025, bringing in $5.95M, or 76.1% of the $7.83M total across its two product and service lines.
Every figure comes from Aclaris Therapeutics' annual financial filings, as reported. Each line keeps the name Aclaris Therapeutics gives it, and years follow its fiscal calendar.
Aclaris Therapeutics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.